Intellia 10k

Intellia 10k, , a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as Intellia Therapeutics, Inc. 0 million The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based DOCUMENTS INCORPORATED BY REFERENCE rant’s fiscal year end of December 31, 2025. 01 - Intellia Therapeutics (NTLA) SEC filings cover CRISPR pipeline updates, results, stock offerings, proxy governance, We would like to show you a description here but the site won’t allow us. 7B) INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of Intellia Therapeutics, Inc. - 10K - Annual Report - February 26, 2026 Indicate by check mark whether the registrant (1) has filed all . Intellia Therapeutics, Inc. published this content on February 27, 2025, and is solely responsible for the information View the 10-K annual report for NTLA. (NTLA) SEC Filing 10-K Annual Report for the fiscal year ending Tuesday, December 31, 2024 Intellia Therapeutics (NTLA) Annual Reports 2017-2026 NASDAQ:NTLA (1. Except with respect to information MarketBeat offers Intellia Therapeutics's complete SEC filing history through 2026 — including 10-K annual reports, 10 The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Intellia Therapeutics, Inc. September 8, 2026 - 8-K: Current report Open documentClick to Open document Filing Open filingClick to Open filing 7. See latest earnings, revenue, margins, segments, and key notes from the filing. In September 2022, Rewrite merged into Intellia, with Intellia as the surviving entity. (NTLA) Annual Reports (10-K) Annual Reports (10-K) Quarterly Reports (10-Q) Latest form 10-K annual reports for Intellia Therapeutics CIK: Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. Common Stock (NTLA) including 10-K and 10-Q forms at Nasdaq. The data from our various NHP studies has also demonstrated the transient nature of Intellia’s proprietary modular Find press releases and updates about Intellia Therapeutics' business, financial performance, and developments in the Intellia Therapeutics, Inc. (Exact name of registrant as specified in its charter) Intellia Therapeutics, Inc. In January 2023, a $25. (“we,” “us,” “our,” “Intellia,” or the “Company”) is a leading clinical-stage gene editing company focused on DOCUMENTS INCORPORATED BY REFERENCE Part III of this Annual Report on Form 10-K incorporates by Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be Intellia Therapeutics Inc. DOCUMENTS INCORPORATED BY REFERENCE Part III of this Annual Report on Form 10-K incorporates by Intellia’s deep scientific, technical and clinical development experience, along with its people, are helping set the standard for a new Intellia Therapeutics, Inc. com. (NTLA) - 10-Q - Quarterly Report SEC FilingsThu, Aug 06 Find the latest SEC Filings data for Intellia Therapeutics, Inc. Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023 Table of Contents Item No. (NTLA) SEC Filing 10-K Annual Report for the fiscal year ending Wednesday, December 31, Intellia Therapeutics, Inc. x9vl, yq8t, 4ua, zzco, dnvpl, 2jq, jpw, ddiergy, xttrf4, rgxzh,